Home › Trials › NCT07170150

Trontinemab for early symptomatic Alzheimer's disease

A Phase III, Multicenter, Randomized, Double-Blind, Placebo-Controlled, Parallel-Group Efficacy and Safety Study of Trontinemab in Participants With Early Symptomatic Alzheimer's Disease (MCI to Mild Dementia Due to AD)

Phase 3 Interventional Hoffmann-La Roche · NCT07170150

This trial tests whether trontinemab, compared with placebo, can slow cognitive decline and be safe in people with early symptomatic Alzheimer's disease (mild cognitive impairment to mild dementia).

Quick facts

PhasePhase 3
Study typeInterventional
Enrollment800 (estimated)
Ages50 Years to 90 Years
SexAll
SponsorHoffmann-La Roche Industry-sponsored
Drugs / interventionstrontinemab
Locations150 sites (Phoenix, Arizona and 149 other locations)
Trial IDNCT07170150 on ClinicalTrials.gov

What this trial studies

This phase 3 interventional trial enrolls people with early symptomatic Alzheimer's disease who have evidence of amyloid pathology by PET or qualifying CSF and meet cognitive criteria. Participants receive trontinemab or placebo and undergo regular cognitive and functional testing alongside safety monitoring. The protocol requires MRI and biomarker procedures (amyloid PET or CSF) and clinical genotyping at screening and during follow-up. The main goals are to see if trontinemab slows clinical decline and to characterize its safety and biomarker effects in this population.

Who should consider this trial

Good fit: Ideal candidates are adults with early symptomatic Alzheimer's disease (MCI to mild dementia) confirmed by amyloid PET or CSF, with MMSE ≥22 and CDR global score 0.5 or 1.0, who can complete imaging and neuropsychological testing and participate with a study partner.

Not a fit: Patients with more advanced dementia, no evidence of amyloid pathology, inability to undergo required imaging or testing, or who cannot commit to scheduled visits are unlikely to benefit from this trial.

Why it matters

Potential benefit: If successful, trontinemab could slow cognitive decline and delay progression in people with early Alzheimer's disease.

How similar studies have performed: Other anti-amyloid antibody programs have shown mixed results—some reduced brain amyloid and produced modest clinical benefits in early AD, while others did not demonstrate meaningful slowing of decline.

Eligibility criteria

Show full inclusion / exclusion criteria 
Inclusion Criteria:

* Willingness and ability to complete all aspects of the study (including MRI, clinical genotyping, and PET imaging or CSF as applicable) for the duration of the study. The participant should be capable of completing assessments either alone or with the help of the study partner
* Adequate visual and auditory acuity, in the investigator's judgment, sufficient to perform the neuropsychological testing (eyewear and hearing aids are permitted)
* Evidence of AD pathological process, as confirmed on amyloid PET scan. A CSF tau181/Aβ42 ratio may be used as an alternative option if amyloid PET is not available
* Probable AD dementia or MCI due to AD, also known as an Alzheimer's clinical syndrome clinical Stage 3 or Stage 4
* Screening MMSE score ≥ 22 and CDR-GS of 0.5 or 1.0
* Participant- and/or Informant-reported history of cognitive decline with gradual onset and progression over the last 1 year before screening
* A Repeatable Battery for the Assessment of Neuropsychological Status Delayed Memory Index (RBANS DMI) score of 85 or order
* Availability of a "study partner" as defined by the protocol

Exclusion Criteria:

* Any evidence of a condition other than AD that may affect cognition
* History or presence of clinically significant cerebrovascular disease
* History of severe, clinically significant (persistent neurologic deficit or structural brain damage) central nervous system (CNS) trauma
* History or presence of clinically significant intracranial mass
* MRI evidence of significant cerebral abnormalities or inability to tolerate MRI procedures or contraindication to MRI
* Any other medical conditions (e.g., cardiovascular, hepatic, renal disease) which are not stable and adequately controlled or which in the opinion of the investigator could affect the participant's safety in the study or interfere with the study assessments
* History of malignancy with the following exceptions: if considered to be cured; malignancies with a negligible risk of metastasis or death

Where this trial is running

Phoenix, Arizona and 149 other locations

+100 more sites — see ClinicalTrials.gov for the full list.

Study contacts

How to participate

  1. Review the eligibility criteria above with your treating physician.
  2. Visit the official trial page on ClinicalTrials.gov for the most current contact information and recruitment status.
  3. Contact the listed study coordinator or principal investigator to request pre-screening. Pre-screening is free and never obligates you to enroll.
View on ClinicalTrials.gov → Find more trials like this →
Conditions Alzheimers DiseaseEarly Alzheimers DiseaseMild Cognitive ImpairmentMild Dementia
Last reviewed 2026-06-13 by the Find a Trial editorial team. Information on this page is for educational purposes and is not medical advice. Always consult qualified healthcare professionals about clinical trial participation.